KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Edwards Lifesciences (EW) EPS (Weighted Average and Diluted) (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of EPS (Weighted Average and Diluted) data on record, last reported at $0.14 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 78.46% year-over-year to $0.14; the TTM value through Dec 2025 reached $1.81, down 26.12%, while the annual FY2025 figure was $1.81, 74.03% down from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.14 in Q4 2025 per EW's latest filing, down from $0.49 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.78 in Q2 2021 and bottomed at $0.14 in Q4 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.56, with a median of $0.57 recorded in 2024.
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 490.0% in 2021, then tumbled 78.46% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.52 in 2021, then increased by 25.0% to $0.65 in 2022, then decreased by 6.15% to $0.61 in 2023, then increased by 6.56% to $0.65 in 2024, then tumbled by 78.46% to $0.14 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $0.14 in Q4 2025, $0.49 in Q3 2025, and $0.56 in Q2 2025.